8 results about "Rabeprazole" patented technology

The invention discloses a sequential anti-tumor strategy based on combination of improved tumor microenvironment (TME) and CAR T and application of the sequential anti-tumor strategy, belongs to the technical field of biological medicine, and particularly relates to a sequential anti-tumor strategy based on combination of improved tumor microenvironment (TME) and CAR T. According to the strategy, tumor fibrosis and an acidic microenvironment are improved at the same time by applying a tumor-associated fibroblast (CAF) targeted drug and a proton pump inhibitor, and then sequential injection of CAR T is performed for combined treatment of solid tumors. Wherein the CAF targeting drug is selected from all-trans retinoic acid, calcipotriol, losartan and minetil, the proton pump inhibitor is selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy firstly destroys a compact physical barrier of a tumor microenvironment, improves acidity of a tumor site, ensures infiltration, survival and proliferation of CAR T at the tumor site, and then utilizes specificity of CAR T to inhibit growth of solid tumors in a targeted manner, especially triple negative breast cancer with a high malignancy degree.

The present invention relates to a novel pharmaceutical composition having improved stability comprising rabeprazole, a pharmaceutically acceptable salt or hydrate thereof, and a method for producing the same. The pharmaceutical composition, according to the present invention, comprising rabeprazole and a pharmaceutically acceptable salt thereof as active ingredients, exhibits excellent stability in gastric juice having low pH, and can minimize side effects.

The application discloses a sequential anti-tumor strategy based on improvement of tumor microenvironment (TME) combined with CAR T and application thereof, and belongs to the technical field of biological medicine, which simultaneously improves tumor fibrosis and acid microenvironment by applying tumor-related fibroblast (CAF) targeting drugs and proton pump inhibitors, and sequentially injects CAR T combined therapy for solid tumors, wherein the CAF targeting drugs are selected from tretinoin, calcipotriol, losartan and minnelide, the proton pump inhibitors are selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy first destroys the dense physical barrier of the tumor microenvironment, improves the acidity of the tumor site, ensures the infiltration, survival and proliferation of CAR T at the tumor site, and then targets and inhibits the growth of solid tumors, especially high-malignancy triple-negative breast cancer, by using the specificity of CAR T.

The present application provides a method for quantitatively analyzing acid-suppressing drugs by a high-performance liquid chromatography-tandem mass spectrometry device, comprising: preparing a sample solution containing the acid-suppressing drug; injecting the sample solution into the high-performance liquid chromatography-tandem mass spectrometry device to obtain a mass chromatogram; and quantitatively analyzing the acid-suppressing drug using an internal standard method according to the mass chromatogram, wherein the acid-suppressing drug is selected from: esomeprazole, rabeprazole, ilaprazole, lansoprazole, pantoprazole and vonoprazan fumarate; using a mixed mobile phase consisting of mobile phase A and mobile phase B for gradient elution in the high-performance liquid chromatography, wherein mobile phase A is an acetonitrile solution containing formic acid or a water-acetonitrile mixture containing ammonia and ammonium acetate (water: acetonitrile volume ratio: 1:99-10:90); and mobile phase B is selected from an aqueous solution containing ammonium acetate, an aqueous solution containing formic acid and ammonium acetate, an aqueous solution containing ammonia and ammonium acetate, and an aqueous solution containing ammonia and ammonium formate.

This utility model relates to the field of reaction vessel technology, specifically a reaction vessel for processing rabeprazole sulfide. It includes a reaction vessel body, with three mounting seats fixedly connected to the outer wall of the reaction vessel body. A rotating shaft is fixedly connected to each mounting seat, and a support rod is rotatably connected to the rotating shaft. An attachment lug is fixedly connected to each support rod, and a limit rod is slidably connected to the attachment lug. Two arc-shaped grooves are provided on each mounting seat, and a limit block is fixedly connected to the outer side of each mounting seat. The end of the limit rod engages with a hole in the limit block. First, the reaction vessel body is installed in a designated position, and the end of the limit rod is no longer engaged with the hole in the limit block. Then, the support rod is rotated around the rotating shaft to change its angle. When the support rod rotates to a suitable angle, the end of the limit rod engages with another hole in the limit block, effectively limiting the support rod and quickly adjusting its tilt angle, thus enhancing the overall stability of the reaction vessel body.

The present invention relates to a novel pharmaceutical composition containing rabeprazole, a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a method for preparing the same, which has improved stability. The pharmaceutical composition according to the present invention, which contains rabeprazole or a pharmaceutically acceptable salt thereof as an active ingredient, exhibits excellent stability in gastric juice having a low pH, and can minimize side effects.

The present application provides a polycyclic ketone monooxygenase mutant, the amino acid sequence of which is obtained by mutation of the amino acid sequence shown in SEQ ID NO. 2, and discloses a method for asymmetric biocatalytic synthesis of a lrazole drug based on the mutant. The enzyme catalyst developed based on the present application can be used to asymmetrically catalyze the synthesis of (R)-rabeprazole, lansoprazole and other lrazole compounds under mild conditions using a whole cell or enzyme protein catalytic method, without the need for chemical catalysts, and is environmentally friendly, being a green biocatalytic synthesis route.

The present invention relates to clear stable ready to use (RTU) aqueous injectable compositions of proton pump inhibitor compounds, in particular pantoprazole and rabeprazole and salts thereof and to processes to prepare such compositions. The compositions comprise proton pump inhibitor compounds, L-arginine, at least one antioxidant and at least one chelating agent.